*Curriculum Vitae*

Terry W. Moore, Ph.D.

Assistant Professor

University of Illinois at Chicago

Department of Medicinal Chemistry and Pharmacognosy

833 S. Wood St. (M/C 781)

504 PHARM

Chicago, IL 60612

312.413.1846 (phone)

312.996.7107 (fax)

[twmoore@uic.edu](mailto:twmoore@uic.edu)

[moorelab.publish.uic.edu](http://moorelab.publish.uic.edu)

[My Bibliography](https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/45497423/?sort=date&direction=descending) ● [Google Scholar](http://www.scholar.google.com/citations?user=VvobtmoAAAAJ&hl=en) ● [ResearchGate](http://www.researchgate.net/profile/Terry_Moore7) ● [LinkedIn](http://www.linkedin.com/pub/terry-moore/5/70/2b1) ● [ORCID](http://www.orcid.org/0000-0002-5410-306X)

**Independent Career Experience**

2013–present Assistant Professor of Medicinal Chemistry, University of Illinois at Chicago

**Other Professional Experience**

2009–2013 Postdoc, Emory Institute for Drug Development, GA (Dennis Liotta)

2008–2009 Postdoc, University of Illinois at Urbana-Champaign, IL (John Katzenellenbogen)

2003–2008 Graduate Student, University of Illinois at Urbana-Champaign (John Katzenellenbogen)

2002–2003 Associate Scientist, ArQule, Inc., MA

2001–2001 Visiting Scientist, University of Birmingham, UK (Richard Douthwaite)

2000–2001 Lab Coordinator, Abilene Christian University Department of Chemistry, TX

**Education**

2003–2008 Ph.D. in chemistry, University of Illinois at Urbana-Champaign, IL

1996–2000 B.A. in biochemistry, *summa cum laude*, Abilene Christian University, TX

**Summary**

Terry W. Moore is an assistant professor of medicinal chemistry in the College of Pharmacy at the University of Illinois at Chicago. His research program focuses on designing, synthesizing, and characterizing new small molecule and peptide probes to modulate transcription factors, including nuclear receptors and NRF2. Dr. Moore’s lab at UIC uses the tools of synthetic medicinal chemistry, peptide chemistry, drug discovery and chemical biology. He is a member of the Long-Range Planning Committee of the Division of Medicinal Chemistry of the American Chemical Society, and he is a member of the organizing committee of the 2019 EFMC/MEDI Frontiers in Medicinal Chemistry Symposium in Krakow. Dr. Moore is a guest co-editor of an upcoming special issue of *Molecular and Cellular Endocrinology* on “Alternative Nuclear Receptor Ligands.” Because of these efforts, Dr. Moore was named the UIC “Rising Star” Researcher of the Year for the Basic Life Sciences in 2018.

**Publications Overview**

H-index ([Google Scholar](https://scholar.google.com/citations?user=VvobtmoAAAAJ&hl=en&authuser=1)): 14

i-10 Index ([Google Scholar](https://scholar.google.com/citations?user=VvobtmoAAAAJ&hl=en&authuser=1)): 17

Total publications: 33

Papers in reviewed journals: 31

Book chapters: 2

Patents and Patent Applications: 5

**Publications from Independent Career**

**Peer-reviewed Journal Articles**

1. Kornelia J. Skowron, K. J.; Booker, K. M.; Cheng, C.; Creed, S.; David, B. P.; Lazzara, P. R.; Lian, A.; Siddiqui, Z.; Speltz, T. E.; **Moore, T. W.** Steroid Receptor/Coactivator Binding Inhibitors: An Update. **Accepted pending minor revisions.** (literature review)
2. Skowron, K. J.; Speltz, T. E.; **Moore, T. W.** Recent Structural Advances in Constrained Helical Peptides. *Medicinal Research Reviews,* **2019,** *39,* 749–770. doi: 10.1002/med.21540770. PMID: 30307621. (literature review).
   * Artwork selected for back cover
3. Richardson, B. G.; Jain, A. D.; Potteti, H.; Lazzara, P. R.; David, B. P.; Tamatam, C.; Choma, E.; Skowron, K. J.; Dye, K.; Siddiqui, Z.; Wang, Y-. T. Krunic, A.; Reddy, S. P.; **Moore, T. W.** Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear factor (erythroid-derived 2)-like 2 (NRF2) Inhibitors. *Journal of Medicinal Chemistry*, **2018,** *61,* 8029–8047. doi: 10.1021/acs.jmedchem.8b01133. PMID: 30122040.
4. David, B. P.; Dubrovskyi, O.; Speltz, T. E.; Wolff, J. J.; Frasor, J.; Sanchez, L. M.; **Moore, T. W.** Using Tumor Explants for Imaging Mass Spectrometry Visualization of Unlabeled Peptides and Small Molecules. *ACS Medicinal Chemistry Letters*, **2018,** *9,* 768–772. doi: 10.1021/acsmedchemlett.8b00091. PMID: 30034616, PMCID: PMC6047048

* Artwork selected for cover

1. Speltz, T. E.; Mayne, C. G.; Fanning, S. W.; Siddiqui, Z.; Tajkhorshid, E.; Greene, G. L.; **Moore, T. W.** A ‘Cross-Stitched’ Peptide with Improved Helicity and Proteolytic Stability. *Organic and Biomolecular Chemistry,* **2018,** *16,* 3702–3706. doi: 10.1039/C8OB00790J*.* PMID: 29725689, PMCID: PMC5993042
2. Speltz, T. E.; Danes, J. M.; Stender, J. D.; Frasor, J.; **Moore, T. W.** A cell-permeable stapled peptide inhibitor of the estrogen receptor/coactivator interaction. *ACS Chemical Biology,* **2018,** *13,* 676–684. doi: 10.1021/acschembio.7b01016. PMID: 29309722. PMCID: PMC6057476.
3. Yao, Y.; Delgado-Rivera, L.; Samareh Afsari, H.; Yin, L.; Thatcher, G. R. J.; **Moore, T. W.;** Miller, L. W. Time-gated detection of enzymatically produced hydrogen sulfide: design, synthesis and application of lanthanide based probe. *Inorganic Chemistry*, **2018,** *57,* 681–688. doi: 10.1021/acs.inorgchem.7b02533. PMID: 29281273, PMCID: PMC5791759.
4. Popovich, N. G.; Okorie-Awe, C.; Crawford, S. Y.; Balcazar, F. E.; Vellurattil, R. P.; **Moore, T. W.;** Schriever, A. E. Assessing Students' Impressions of the Cultural Awareness of College of Pharmacy Faculty and Students. *American Journal of Pharmaceutical Education,* **2018**, *82,* 6161*.* doi: 10.5688/ajpe6161.
   * Winner of the Rufus A. Lyman Award, which is presented annually to the authors of the best paper published in the *American Journal of Pharmaceutical Education.*
5. Yao, Y.; Kong, C.; Yin, L.; Jain, A. D.; Ratia, K.; Thatcher, G. R.; **Moore, T. W.;** Driver, T. G.; Miller, L. W. Time-gated detection of cystathionine γ-lyase activity and inhibition with a selective, luminogenic hydrogen sulfide sensor. *Chemistry – A European Journal,* **2017,** *23,* 752–756. doi: 10.1002/chem.201604786. PMID: 27734530, PMCID: PMC5250566.

* *Artwork selected for Frontispiece (See doi: 10.1002/chem.201604786)*

1. Speltz, T. E.; Fanning, S. W.; Mayne, C. G.; Fowler, C.; Tajkhorshid, E.; Greene, G. L.; **Moore, T. W.** Stapled Peptides with γ-Methylated Hydrocarbon Chains for the Estrogen Receptor/Coactivator Interaction. *Angewandte Chemie International Edition* **2016,** *55,* 4252–4255. doi: 10.1002/anie.201510557 and 10.1002/ange.201510557. PMID: 26928945, PMCID: PMC4964982.

* Chosen by editors as “Hot Paper” for “importance in a rapidly evolving field of high current interest”
* Artwork selected for Inside Cover (See doi: 10.1002/anie.201601641)

1. Xiong, R.; Patel, H.; Gutgesell, L.; Zhao, J.; Delgado-Rivera, L.; Pham, T.; Zhao, H.; Carlson, K. E.; Martin, T. F.; Katzenellenbogen, J. A.; **Moore, T. W.;** Tonetti, D.; Thatcher, G. R. J. Selective human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. *Journal of Medicinal Chemistry* **2016,** *59*, 219–237. doi: 10.1021/acs.jmedchem.5b01276*.* PMID: 26681208, PMCID: PMC4779956.
2. Jain, A. D.; Potteti, H.; Richardson, B. G.; Kingsley, L.; Luciano, J. P.; Ryuzoji, A. F.; Lee, H.; Krunic, A.; Mesecar, A. D.; Reddy, S. P.; **Moore, T. W.** Probing the Structural Requirements of Non-electrophilic Naphthalene-Based Nrf2 Activators. *European Journal of Medicinal Chemistry* **2015,***103,* 252–268. doi:10.1016/j.ejmech.2015.08.049. PMID: 26363505, PMCID: PMC4600463.
3. Richardson, B. G.; Jain, A. D.; Speltz, T. E.; **Moore, T. W.** Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway. *Bioorganic and Medicinal Chemistry Letters* **2015,** *25,* 2261–2268.doi:10.1016/j.bmcl.2015.04.019. PMID: 25937010, PMCID: PMC4643947. (literature review)

**Publications from Mentored Career**

**Peer-reviewed Journal Articles**

1. Zhu, S.; Kisiel, W.; Lu, Y. J.; Petersen, L. C.; Ndungu, J. M.; **Moore, T. W.;** Parker, E. T.; Sun, A.; Sarkaria, J. N.; Snyder, J. P.; Liotta, D. C.; Brat, D. J.; El-Rayes, B. F.; Shoji, M. Visualizing cancer and response to therapy *in vivo* using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. *Journal of Drug Targeting* **2014,** *23,* 257–265. doi: 10.3109/1061186X.2014.988217. PMID: 25510254, PMCID: PMC4625384.
2. Zhu, S.; Kisiel, W.; Lu, Y. J.; Petersen, L. C.; Ndungu, J. M.; **Moore, T. W.;** Parker, E. T.; Sun, A.; Liotta, D. C.; El-Rayes, B. F.; Brat, D. J.; Snyder, J. P.; Shoji, M. Tumor angiogenesis therapy using targeted delivery of paclitaxel to the vasculature of breast cancer metastases. *Journal of Drug Delivery* **2014,** *2014,* Article ID 865732, 12 pages.doi: 10.1155/2014/865732. PMID: 25574399. PMCID: PMC4273585.
3. Grimmer, C.; **Moore, T. W.**; Padwa, A.; Prussia, A.; Wells, G.; Wu, S.; Sun, A.; Snyder, J. P. Antiviral Atropisomers: Conformational Energy Surfaces by NMR for Host-Directed Myxovirus Blockers. *Journal of Chemical Information and Modeling* **2014,** *54,* 2214–2223. doi: 10.1021/ci500204j. PMID: 25058809.
4. Zhu, S.; **Moore, T. W.;** Morii, N.; Howard, R. B.; Culver, D.; Arrendale, R. F.; Reddy, P.; Evers, T. J.; Zhang, H.; Sica, G.; Sun, A.; Fu, H.; Khuri, F. R.; Shin, D. M.; Snyder, J. P.; Shoji, M. Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts. *Current Cancer Drug Targets* **2014,** *14,* 380–393. doi: 10.2174/1568009614666140312163524. PMID: 24628271.
5. Yamaguchi, M.; Zhu, S.; Zhang, S.; Wu, D.; **Moore, T. M.;** Snyder, J. P.; Shoji, M. Curcumin Analogue UBS109 Prevents Bone Loss in Breast Cancer Bone Metastasis Mouse Model: Involvement in Osteoblastogenesis and Osteoclastogenesis. *Cell and Tissue Research* ***2014,*** *357,* 245–252*.*doi:10.1007/s00441-014-1846-4. PMID: 24723227.
6. **Moore, T. W.;** Zhu, S.; Randolph, R.; Shoji, M.; Snyder, J. P. Liver S9 Fraction-Derived Metabolites of Curcumin Analog UBS109. *ACS Medicinal Chemistry Letters* **2014,** *5,* 288–292*.*doi: 10.1021/ml4002453.PMID: 24900828. PMCID: PMC4027781.
7. **Moore, T. W.;** Sana, K.; Yan, D.; Krumm, S. A.; Thepchatri, P.; Snyder, J. P.; Marengo, J.; Arrendale, R. F.; Prussia, A. J.; Natchus, M. G.; Liotta, D. C.; Plemper, R. K.; Sun, A. Synthesis and Metabolic Studies of Host-Directed Inhibitors for Anti-Viral Therapy. *ACS Medicinal Chemistry Letters* **2013,** *4,* 762–767. doi: 10.1021/ml400166b. PMID: 23956816. PMCID: PMC3743129.
8. Brown, A.; Shi, Q.; **Moore, T. W.**; Yoon, Y.; Prussia, A.; Maddox, C.; Liotta, D. C.; Shim, H.; Snyder, J. P. Monocarbonyl Curcumin Analogs: Heterocyclic Pleiotropic Kinase Inhibitors that Mediate Anti-Cancer Properties. *Journal of Medicinal Chemistry* **2013,** *56,* 3456–3466. doi: 10.1021/jm4002692. PMID: 23550937. PMCID: PMC3927397.
9. **Moore, T. W.**; Sana, K.; Yan, D.; Thepchatri, P.; Ndungu, J. M.; Saindane, M. T.; Natchus, M. G.; Liotta, D. C.; Plemper, R. K.; Snyder, J. P.; Sun, A. Asymmetric Synthesis of Host-Directed Inhibitors of Myxoviruses. *Beilstein Journal of Organic Chemistry* **2013,** *9,* 197–203. doi: 10.3762/bjoc.9.23. PMID: 23400228. PMCID: PMC3566758.
10. Yamaguchi, M.; **Moore, T. W.**; Sun, A.; Snyder, J. P.; Shoji, M. Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis *in vitro*. *Integrative Biology* **2012,** *4,* 905–913.doi: 10.1039/c2ib20045g. PMID: 22751853.
11. Zhu, S.; **Moore, T. W.**; Lin, X.; Morii, N.; Mancini, A.; Howard, R. B.; Culver, D.; Arrendale, R. F.; Reddy, G. P.; Evers, T. J.; Zhang, H.; Sica, G.; Chen, Z. G.; Sun, A.; Fu, H.; Khuri, F. R.; Shin, D. M.; Snyder, J. P.; Shoji, M. Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. *Integrative Biology* **2012,** *4,*633–640**.** doi: 10.1039/c2ib20007d. PMID: 22532032. PMCID: PMC3734847.
12. Olivera, A.; **Moore, T. W.**; Sun, A.; Hu, F.; Liotta, D. C.; Snyder, J. P.; Shim, H.; Marcus, A. I.; Miller, A. H.; Pace, T. W .W. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. *International Immunopharmacology* **2012,** *12,* 368–377.doi: 10.1016/j.intimp.2011.12.009. PMID: 22532032. PMCID: PMC3734847.
13. Sun, A.; **Moore, T. W.**; Gunther, J. R.; Kim, M. S.; Rhoden, E.; Du, Y.; Fu, H.; Snyder, J. P.; Katzenellenbogen, J. A. Discovering Small Molecule Estrogen Receptor α/Coactivator Binding Inhibitors: High-Throughput Screening, Ligand Development, and Models for Enhanced Potency. *ChemMedChem* **2011,** *6,* 654–666. doi: 10.1002/cmdc.201000507. PMID: 21365764. PMCID: PMC3177402.
14. **Moore, T. W.**; Gunther, J. R.; Katzenellenbogen, J. A. Probing the Topological Tolerance of Multimeric Protein Interactions: Evaluation of an Estrogen/Synthetic Ligand for FK506 Binding Protein Conjugate. *Bioconjugate Chemistry* **2010,** *21,* 1880–1889. doi: 10.1021/bc100266v. PMID: 20919698. PMCID: PMC2967433.
15. **Moore, T. W.**; Mayne, C. G.; Katzenellenbogen, J. A. Not picking pockets: Nuclear Receptor Alternate-site Modulators (NRAMs). *Molecular Endocrinology* **2010,** *24,* 683–695. doi: 10.1210/me.2009-0362. PMID: 19933380. PMCID: PMC2852352. (literature review)

* Artwork was selected by Editor for Cover

1. Gunther, J. R.; Du, Y.; Rhoden, E.; Lewis, I.; Revennaugh, B.; **Moore, T. W.**; Kim, S. H.; Dingledine, R.; Fu, H.; Katzenellenbogen, J. A. A set of time-resolved fluorescence resonance energy transfer assays for the discovery of inhibitors of estrogen receptor-coactivator binding. *Journal of Biomolecular Screening* **2009**, *14,* 181–193. doi: 10.1177/1087057108329349. PMID: 19196699. PMCID: PMC2731238.
2. Gunther, J. R.; **Moore, T. W.**; Collins, M. L.; Katzenellenbogen, J. A. Amphipathic benzenes are designed inhibitors of the estrogen receptor α/steroid receptor coactivator interaction. *ACS Chemical Biology* **2008**, *3,* 282–286. doi: 10.1021/cb800056r. PMID: 18484708. PMCID: PMC2427189.
3. Clews, P. K.; Douthwaite, R. E.; Kariuki, B. M.; **Moore, T.**; Taboada, M. Layered compounds incorporating 9,9'-spirobifluorene: Hydrogen-bonded and metal-organic networks derived from 9,9'-spirobifluorene-2,2',7,7'-tetracarboxylic acid. *Crystal Growth and Design* **2006**, *6,* 1991–1994. doi:10.1021/cg060007d.
4. **Moore, T.**; Kiely, C.; Reeves, P. C. Electronic properties of the trimethylenemethaneiron tricarbonyl group. *Journal of Organometallic Chemistry* **2001**, *620,* 308–312. doi:10.1016/S0022-328X(00)00812-3.

**Book Chapters**

1. **Moore, T. W.;** Gunther, J. R.; Katzenellenbogen, J. A. Estrogen receptor alpha/co-activator interaction assay - TR-FRET. In *PROTEIN-PROTEIN INTERACTIONS: Methods and Applications; Second Edition.*  Methods in Molecular Biology; C. Meyerkord and H. Fu, Eds.; Humana Press: New York, 2015, Vol. 1278, p. 545–553. doi: 10.1007/978-1-4939-2425-7\_36. PMID: 25859975, PMCID: PMC4893311.
2. **Moore, T. W.**; Katzenellenbogen, J. A. Inhibitors of nuclear hormone receptor/coactivator interactions. *Annual Reports in Medicinal Chemistry* **2009**, *44,* 443–457. doi:10.1016/S0065-7743(09)04421-2.

**Patents and Patent Applications**

1. International Patent Application PCT/US19/25464. 1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION. 04/02/2019.
2. US Provisional Patent Application No. 62/653,650. Propionate and 1,4-N,C substituted Naphthalene Inhibitors of Keap1/Nrf2 Protein-Protein Interaction. 04/06/2018.
3. US Provisional Patent Application No. 62/121,077. Inhibitors of the Keap1/Nrf2 interaction. 02/26/2015.
4. US Provisional Patent Application No. 62/032,279. Inhibitors of KEAP1-NRF2 Interaction and Methods of Use. 08/01/2014
5. US Provisional Patent Application No. 61/949,308. Novel amino acids and peptides for inhibiting nuclear receptor/coactivator interactions. 03/07/2014.
6. US Provisional Patent Application No. 61/949,301. Inhibitors of the Keap1/Nrf2 interaction. 03/07/2014.

**Research Support**

**Overview**

Total funding attributed to TWM: >$1,300,000

Active grants: 3

Completed grants: 9

Pending grants: 6

**Current**

1R01 AR069541-01A1 (Moore, PI) 04/01/17 – 03/31/20 1.35 academic

National Institutes of Health, NIAMS $1,042,272 (74% to TWM) 0.38 summer

Non-covalent Nrf2 activators for the treatment of chronic wounds

We will test the hypothesis that non-covalent, pharmacologic activation of Nrf2 will accelerate wound healing, which could lead to new therapeutics to treat chronic wounds.

1R01 HL136946-01 (Reddy, PI; Moore, Co-I) 04/01/17 – 03/31/22 0.43 academic

National Institutes of Health, NHLBI $1,942,780 (10% to TWM) 0.12 summer

Role of Nrf2 in Alveolar epithelial Cell Regeneration During Lung Repair

We will test the hypothesis that Nrf2 activation will accelerate alveolar epithelial cell repair post-injury.

Hans W. Vahlteich Research Award (Moore, PI) 04/01/17 – no expiration No set effort

Vahlteich Research Award (UIC Internal) $50,000 (100% to TWM)

Selective Peptide Antagonists of a Mutant Estrogen Receptor

This is an internal award in the UIC College of Pharmacy to support new and junior faculty.

**Pending**

Moore, PI 07/01/19 – 06/30/23 1.35 academic

American Cancer Society Research Scholar Grant $792,000 (74% to TWM) 0.38 summer

Selective Antagonists of Mutant Estrogen Receptors

The goal of this project is to create mutant-selective inhibitors of the estrogen receptor/coactivator interaction.

Moore, Radhakrishnan, MPI 07/01/19 – 06/30/21 0.90 academic

National Institutes of Health, NCI R21 $154,155 (100% to TWM) 0.25 summer

HDAC Complex-Specific Inhibitors as Therapeutic Candidates for Triple-Negative Breast Cancer

The goal of this project is to create inhibitors and degraders of SIN3.

Moore, Radhakrishnan, Yu, MPI 09/01/19 – 08/31/21 0.18 academic

Chicago Biomedical Consortium $250,000 (33% to TWM) 0.05 summer

Ligand-independent Mechanisms of Transcriptional Activation in Prostate Cancer

The goal of this project is to develop molecules that inhibit the activation function 1 (AF1) activity of androgen receptor by developing SRC inhibitors.

# Completed

MCB170046 (Moore, PI) 07/01/17 – 06/30/18 No set effort

NSF XSEDE Resource Allocation $22,195 (100% to TWM)

Binding of stapled peptides to estrogen receptor

Molecular Dynamics Simulations of Chemical Probes that Inhibit Protein-Protein Interactions

This was an allocation that provided computational time on XSEDE supercomputers to carry out molecular dynamics simulations.

MCB170046 (Moore, PI) 04/29/17 – 04/28/18 No set effort

NSF XSEDE Resource Allocation $1,739 (100% to TWM)

Binding of stapled peptides to estrogen receptor

This was a Startup allocation that provided computational time on XSEDE supercomputers to carry out molecular dynamics simulations.

1R01 CA188017-01A1 (Thatcher, PI; Moore, Co-I) 04/06/15 – 03/31/18 0.50 academic

National Institutes of Health, NCI R01 $1,436,435 (9% to TWM) 0.14 summer

Partial Agonists at Estrogen Receptor Alpha for Breast Cancer Therapy

Pharmacologic partial agonists will be developed as novel therapeutics with immediate potential benefit in breast cancer.

Moore, Reddy, MPI 07/01/15 – 06/30/17 No set effort

Chancellor’s Discovery Fund Award $35,000 (50% to TWM)

Development of Nrf2 Activators for the Treatment of Idiopathic Pulmonary Fibrosis

Optimized non-covalent small molecule Nrf2 activators will be used to revert pulmonary fibrotic phenotypes in fibroblasts *ex vivo* and *in vivo*

Moore, Reddy, MPI 01/01/16 – 12/31/16 No set effort

Michael Reese Research and Education Fund $50,000 (50% to TWM)

Nrf2 activators to treat idiopathic pulmonary fibrosis

The goal of this project is to demonstrate that non-covalent small molecule Nrf2 activators show fewer off-target interactions than covalent counterparts.

CBC C-057 (Moore, Greene, Frasor, MPI) 03/01/15 – 02/28/17 0.18 academic

Chicago Biomedical Consortium Catalyst Grant $133,300 (44% to TWM) 0.06 summer

Photoaffinity-based Protein Profiling Approach to Discover Estrogen Receptor/Coactivator Inhibitors

The goal of this project is to develop a proteomics-driven approach to develop high-affinity, high-potency ER/coactivator inhibitors and define their mechanism in wild-type and resistant forms of ER.

1UH2HL123610-01 (Prabhakar, PI; Moore, Co-I) 09/01/14 – 06/30/16 0.63 academic

National Institutes of Health, NHLBI U54 $1,568,928 (2% to TWM) 0.18 summer

Therapeutic targeting of carotid body for sleep-disordered breathing

The goal of this project is to develop novel inhibitors of cystathione γ-lyase (CSE) for sleep apnea.

# HTS-015 (Moore, Hickok, Prabhakar, MPI) 01/01/14 – 12/31/14 No set effort

# Chicago Biomedical Consortium HTS grant $10,000 (matching funds)

Inhibition of cystathionine γ-lyase as a therapeutic approach for relief of sleep disordered breathing

The goal of this project is to develop and carry out a high-throughput screen for inhibitors of cystathione γ-lyase.

2014-01156-00-00 (Moore, PI) 01/01/14 – 12/31/14 No set effort

American Association of Colleges of Pharmacy $10,000 (100% to TWM)

"Tucked" Stapled Peptides for the Estrogen Receptor/Coactivator Interaction

The goal of this project is to develop tether-functionalized stapled peptides for the estrogen receptor/coactivator interaction.

Moore, PI 02/01/11 ­– 05/31/12 2.4 academic

Emory University Head and Neck Cancer SPORE $35,000 (100% to TWM)

Development of Nrf2 Activators as Oral Cancer Chemopreventive Agents

The goal of this project is to test analogs of the natural product curcumin in mouse models of head and neck cancer chemoprevention.

Moore, PI 08/01/05 – 07/31/06 9.0 academic

Pfizer Fellowship for Diversity in Organic Chemistry $26,000 3.0 summer

Development of Coactivator Binding Inhibitors for the Estrogen Receptor

This was a one-year fellowship from Pfizer to support my graduate stipend.

**Presentations from Independent Career**

**Seminars at Other Universities**

1. Development of chemical probes that target estrogen receptor and Nrf2. Technische Universiteit Eindhoven Chemical Biology Group, Eindhoven, NL, 05/14/18.
2. Development of chemical probes for transcription factor interactions. University of Kansas Department of Medicinal Chemistry, Lawrence, KS, 05/03/18.
3. Development of chemical probes for transcription factor interactions. University of Minnesota Department of Medicinal Chemistry, Minneapolis, MN, 04/18/18.
4. Development of chemical probes for transcription factor interactions. University of Michigan Department of Medicinal Chemistry, Ann Arbor, MI, 04/12/18.
5. Development of chemical probes for transcription factor interactions. University of Iowa Department of Pharmaceutical Sciences and Experimental Therapeutics, Iowa City, IA, 03/26/18.
6. Development of chemical probes for transcription factor interactions. University of North Carolina Greensboro Department of Chemistry, Greensboro, NC, 03/23/18.
7. Development of chemical probes for transcription factor interactions. Duquesne University Department of Medicinal Chemistry, Pittsburgh, PA, 03/15/18.
8. Development of chemical probes for transcription factor interactions. National Cancer Institute, Frederick, MD, 03/09/18.
9. Development of chemical probes for transcription factor interactions. Purdue University Department of Medicinal Chemistry and Molecular Pharmacology, West Lafayette, IN, 03/01/18.
10. Development of chemical probes for transcription factor interactions. Virginia Tech Department of Chemistry, Blacksburg, VA, 02/23/18.
11. Development of chemical probes for transcription factor interactions. University of Southern California Department of Pharmacology and Pharmaceutical Sciences Los Angeles, CA, 02/16/18.
12. Development of chemical probes for transcription factor interactions. Northern Illinois University Department of Chemistry, Dekalb, IL, 04/17/17.
13. Branching Out: γ-Methylated Hydrocarbon Stapled Peptides for the Estrogen Receptor/Coactivator Interaction. University of Wisconsin-Milwaukee Department of Chemistry, Milwaukee, WI, 01/29/16.
14. Medicinal Chemistry Approaches to Inhibiting Protein-Protein Interactions. DePaul University Department of Chemistry, Chicago, IL, 11/10/15.
15. Naphthalene-based Activators of the Transcription Factor Nrf2. UIC Rockford College of Pharmacy Research Colloquium, Rockford, IL, 04/06/15.

**Conference Seminars**

1. Optimization of stapled peptide inhibitors of the estrogen receptor/coactivator interaction. 255th American Chemical Society Annual Meeting, New Orleans, LA, 03/21/18.
2. Optimization of non-covalent Nrf2 activators for use in models of chronic wound healing. MEDI Young Investigator’s Symposium at the 255th American Chemical Society Annual Meeting, New Orleans, LA, 03/19/18.
3. Development of stapled peptide inhibitors of the estrogen receptor/coactivator interaction. Annual Meeting of the Endocrine Society ENDO 2018, Chicago, IL, 03/17/18.
4. Stapled Peptide Inhibitors of the Estrogen Receptor/Coactivator Interaction.Chemistry and Biology of Peptides Gordon Research Conference, Ventura, CA, 02/15/18.
5. Tether-functionalized Stapled Peptides for the Estrogen Receptor/Coactivator Interaction. Cambridge Healthtech Institute Macrocycles in Drug Discovery Conference, San Diego, CA, 04/26/17.

**Conference Posters**

1. Functionalized Stapled Peptides for the Estrogen Receptor/Coactivator Interaction. American Peptide Society Symposium, Whistler, BC, 06/21/17.
2. Functionalized Stapled Peptides for the Estrogen Receptor/Coactivator Interaction. Bioorganic Chemistry Gordon Research Conference, Andover, NH, 06/14/17.
3. Non-Electrophilic Activators of Nrf2. Medicinal Chemistry Gordon Research Conference. New London, NH, 08/07/16.
4. Engineering Natural Functional Groups from Leucine and Isoleucine into Stapling Amino Acids. Chemistry and Biology of Peptides Gordon Research Conference, Ventura, CA, 02/21/16.
5. Engineering Natural Functional Groups from Leucine and Isoleucine into Stapling Amino Acids. 250th American Chemical Society Annual Meeting, Boston, MA, 08/17/15.
6. Engineering Natural Functional Groups from Leucine and Isoleucine into Stapling Amino Acids. Poster presented at the Gordon Research Conference in Bioorganic Chemistry, Andover, NH, 06/07/15.
7. A scaffold-hopping approach to discovery Nrf2/Keap1 Inhibitors. Cambridge Healthtech Institute Protein-Protein Interactions Conference, San Diego, CA 04/21/15.
8. Non-Electrophilic Activators of Nrf2. Medicinal Chemistry Gordon Research Conference. New London, NH 08/03/14.

**Honors/Awards**

2018–2019 Member, EFMC-ACS MEDI Frontiers Symposium Organizing Committee, Krakow, PL

2018–2020 Member, Early Career Board, *ACS Medicinal Chemistry Letters*

2018–2021 Member, ACS MEDI Long-Range Planning Committee

2018 MEDI Young Investigator Symposium Awardee, ACS National Meeting, New Orleans

2018 UIC “Rising Star” award winner in the Basic Life Sciences

2017 UIC College of Pharmacy Vahlteich Research Award

2016 NSF Workshop for Early Career Faculty

2015 NIGMS Workshop for New Faculty in Organic and Biological Chemistry

2014 UIC College of Pharmacy P1 Teacher of the Semester

2014 American Association of Colleges of Pharmacy New Investigator Award

2011 The Anthony Shuker Scientific Poster Award at the Georgia Life Sciences Summit

2011 Emory Head and Neck Cancer SPORE Career Development Award

2005 Pfizer Fellowship Supporting Diversity in Organic Chemistry

2003–2005 The “Incomplete List” of Teachers Ranked as Excellent by Their Students

2003 University of Illinois Roger Adams Fellowship

2000 Abilene Christian University Tommy J. McCord Scholarship for Chemical Research

2000 Abilene Christian University Paul C. Witt Award for Chemistry

2000 Abilene Christian University Richard Thompson Memorial Scholarship

2000 Alpha Chi Honor Society

1996–2000 United States Department of Education Robert C. Byrd Honors Scholarship

1996–2000 Abilene Christian University Presidential Scholarship

1996 Phi Eta Sigma Freshman Honor Society

**Teaching During Independent Career**

**Courses Team-taught**

1. PHAR 331/422: Fundamentals of Drug Action I (~200 students)
2. MDCH 561: Principles of Medicinal Chemistry (~5 students)
3. MDCH 571: Organic Medicinal Chemistry II (~5 students)
4. MDCH 507: Drug Discovery, Design and Development (~15 students)
5. PMPR 355: Seminar in Pharmacy Research (~20 students)
6. MDCH 594: Special Topics in Medicinal Chemistry (~10 students)

**Courses Coordinated**

1. MDCH 595: Seminar in Medicinal Chemistry (~60 students)
2. MDCH 561: Principles of Medicinal Chemistry (~5 students)

**Graduate Students Mentored**

1. Thomas Speltz (2014–2018; current: postdoc, University of Chicago)
2. Benjamin Richardson (2014–2018; current: postdoc, Scripps Research Institute Florida)
3. Brian David (2015–present)
4. Zamia Siddiqui (2018–present)
5. Kornelia Skowron (2018–present)

**Postdoctoral Fellows Mentored**

1. Atul Jain (2013–2016; current: Staff Scientist, Northwestern University)
2. Phillip Lazzara (2016–present)

**Graduate Student Preliminary Exam Committees**

1. Hitisha Patel (2014; adviser: Greg Thatcher)
2. Rui Xiong (2014; adviser: Greg Thatcher)
3. Shuai Wang (2014; adviser: Judy Bolton)
4. Thomas Hanigan (2015; adviser: Pavel Petukhov)
5. Emily Thayer (2015; adviser: Greg Thatcher)
6. Sue Lee (2016; adviser: Greg Thatcher)
7. Laura Rodgers (2016; adviser: Joanna Burdette)
8. Tim Langridge (2017, adviser: Rick Gemeinhart)
9. Obinna Mbachu (2017, adviser: Judy Bolton)
10. Yunlong Lu (2018, adviser: Greg Thatcher)
11. Ammar Jastaniah (2018, adviser: Greg Thatcher)
12. Ryan Hitzman (2018, adviser: Judy Bolton)
13. Tania Mutchie (2018, adviser: Alexander Arnold, UW-Milwaukee)

**Graduate Student Dissertation Committees**

1. Engin Yapici (Ph.D., chemistry, 2014; adviser: Larry Miller)
2. Quyen Nguyen (Ph.D., chemistry, 2014; adviser: Tom Driver)
3. May Fern Toh (Ph.D., pharmacognosy, 2014; adviser: Joanna Burdette)
4. Hao Lei (Ph.D., medicinal chemistry, 2015; adviser: Michael Johnson)
5. Chen Kong (Ph.D., chemistry, 2015; adviser: Tom Driver)
6. Hitisha Patel (Ph.D., medicinal chemistry, 2016; adviser: Greg Thatcher)
7. Ronak Gandhi (Ph.D., medicinal chemistry, 2016; adviser: Greg Thatcher)
8. Wiktoria Pace (Ph.D., chemistry, 2016, adviser: Laura Anderson)
9. Xiaoguang Liu (Ph.D., chemistry, 2016, adviser: Justin Mohr)
10. Rui Xiong (Ph.D., medicinal chemistry, 2016, adviser: Greg Thatcher)
11. Navendu Jana (Ph.D. chemistry, 2016, adviser: Tom Driver)
12. Shuai Wang (Ph.D., medicinal chemistry, 2016, adviser: Judy Bolton)
13. Yongchao Li (Ph.D., chemistry, 2017, adviser: Richard van Breemen)
14. Ali Mohamadi (Ph.D., chemistry, 2017, adviser: Larry Miller)
15. Thomas Hanigan (Ph.D., medicinal chemistry, 2017, adviser: Pavel Petukhov)
16. Emily Pierce (Ph.D., medicinal chemistry, 2018, adviser: Greg Thatcher)
17. Sue Lee (Ph.D., medicinal chemistry, 2018, adviser: Greg Thatcher)
18. Lauren Gutgesell (Ph.D., medicinal chemistry, 2019, adviser: Greg Thatcher)
19. Yunlong Lu (Ph.D., medicinal chemistry, 2019, adviser: Greg Thatcher)
20. Jay Anand (Ph.D., biopharmaceutical sciences, 2019, adviser: John Nitiss)
21. Tanja Florin (Ph.D., pharmacognosy, 2019, adviser: Alexander Mankin)

**Research Rotation Students Mentored**

* 1. Daniel Nosal (Spring 2014)
  2. Obinna Mbachu (Fall 2014)
  3. Ammar Jastiniah (Spring 2015)
  4. Ryan DiFalco (Fall 2015)
  5. Amanda Maldonado (Fall 2017)
  6. Changfeng Cheng (Fall 2018)
  7. Simone Creed (Fall 2018)
  8. Kyle Kremiller (Summer 2019)

**Summer Undergraduate Research Fellows (SURF) Mentored**

1. Ishmael Ochir (2015 ASPET SURF program, current: Pharm.D. student, Roosevelt University)
2. Ewelina Choma (2015, 2016 Riback Fellow, current: Pharm.D. resident, Los Angeles V.A.)
3. Zamia Siddiqui (2016, 2017, Riback Fellow, current: Pharm.D./Ph.D. student, UIC)
4. Zohra Sattar (2017, ASPET SURF program, current: Ph.D. student, Northwestern University)
5. Kenneth Booker (2017, ASPET SURF program, current: B.S. student, UIC)

**Presidential Award Program Students Mentored**

1. Patrick Nwanah (2016–2018; B.S. 2018, current: Epidem. Res. Asst. Rush Prevention Center)
2. Ishmael Ochir (2015–2016; B.S. 2016, current: Pharm.D. student, Roosevelt University)
3. Noor Jibrin (2018-2019); current: B.S. student, UIC)

**Honors College Thesis Students Mentored**

* 1. Kirthi Bellamkonda (B.S., 2015, current: M.D. student, Yale University)
  2. Kenneth Booker (2017–present)
  3. Amy Lian (2018–present)

**Odyssey Scholars Mentored**

* 1. Tahnee Muller (2016; current: B.S. student, University of Chicago)

**ResearcHStart Scholars Mentored**

1. Rohit De (Summer 2016; current: B.S. student, UT Dallas)
2. Jasmine Harris (Summer 2017; current: B.S. student, UIC)

**Honors College Students Mentored**

1. Kevin Bueno (2014–2015)
2. Kevin Chung (2014–2017)
3. Brian Kim (2014–2017)
4. Junhui Zhou (2014–2015)
5. Iliana Guzman (2015–2016)
6. Zamia Siddiqui (2015–2016)
7. Vassilena Tsolova (2015–2018)
8. Samar Ashrafi (2016–present)
9. Colin Collery (2016–2018)
10. Kenneth Booker (2017–present)
11. Elysia Sawyers (2017–present)
12. Yasmeen Hassoun (2018–present)
13. Charles Liu (2018–present)
14. Nathan Wong (2018–present)

**Work Study Students Supervised**

* 1. Andriana Scencirro (2013)
  2. Karolina Blasczcuk (2014)

**Service During Independent Career**

**To the Department**

2014 Strategic Plan Committee

2014 MCP Seminar coordinator

2015 Assistant Professor Hiring committee

2015–2019 Advisory Committee

2017–present Graduate admissions committee

2018 MCP Seminar coordinator

**To the College**

2014–present Committee on Committees

2014–present Diversity Strategic Thinking and Planning Committee

2014 Staff and Faculty Giving Campaign Committee

2014 Poster Judge for COP Research Day

2014 Riback Fellowship proposal reviewer

2015 Poster Judge for COP Research Day

2016–present SURF program selection committee

2017 Hiring Committee, Associate Director for Advancement

2018 Hiring Committee, BPS Pharmaceutics Faculty Search

2018 Strategic Planning Committee

2018 Hiring Committee, Associate Director for Diversity and Inclusion

2018–present Co-Chair, Student Recruitment and Retention Subcommittee of DSTP Committee

**To the University**

2013–present UICentre leadership team committee

2014–present Honors College Faculty Fellow

2014–2015 Poster Judge for Undergraduate Research Day

2015, 2018 Honors College Fellow grant proposal reviewer

2015–2018 Awards Committee, Graduate College

2016–2019 Poster Judge for Cancer Research Day

2019–2020 Hiring Committee, Endowed Organic Chemistry Professor

2019–present Academic Advisory Committee, Biophysics Core

2019–present Diversity Awards Committee, Graduate College

2019–present Executive Committee, Graduate College

**To the Profession**

2014–2015 Poster Judge MIKI meeting-in-miniature

2015–2016 National Medicinal Chemistry Symposium Programming Committee, Chicago, IL

2016–2019 Editorial Board, *AACR Chemistry in Cancer Research*

2018 Participant, Editorial Advisory Board Meeting, *ACS Medicinal Chemistry Letters*

2018–2019 Special Issue Guest editor, *Molecular and Cellular Endocrinology*

2018–2019 EFMC-ACS MEDI Frontiers Symposium Organizing Committee, Krakow, PL

2018–2021 Member, Long-Range Planning Committee of ACS MEDI Division

2018–2020 Member, *ACS Medicinal Chemistry Letters* Early Career Board

2019-2020 Session Organizer, American Chemical Society Meeting, Philadelphia, PA

**Grant Proposal Review Committees**

10/2015 Breast Cancer Now UK

12/2016 Florida Department of Health Bankhead Coley Research Grants

01/2017 University of Wisconsin at Milwaukee Research Grant Initiative

04/2017 NIH U54 Contraception Centers, ZHD1 DSR-L 50

01/2018 University of Wisconsin at Milwaukee Research Grant Initiative

05/2018 University of Nebraska Research Initiative Grants

11/2018 NIH SBIR/STTR Drug Discovery and Development, BCMB-10

02/2019 NSF Review Panel

04/2019 NIH SBIR/STTR Drug Discovery and Development, BCMB-10

**Journal Manuscript Reviews**

*Ad hoc* manuscript reviewer at *ACS Combinatorial Science, ACS Medicinal Chemistry Letters, Angewandte Chemie International Edition, Bioconjugate Chemistry, Bioorganic and Medicinal Chemistry, Bioorganic and Medicinal Chemistry Letters, Biopolymers: Peptide Science, ChemBioChem, Chemical Biology and Drug Design, The Chemical Record, Chemical Research in Toxicology, Chemistry - A European Journal, Chemistry Central Journal, ChemistrySelect, ChemMedChem, Current Topics in Medicinal Chemistry, Drug Discovery Today: Technologies, European Journal of Medicinal Chemistry, Expert Opinion on Therapeutic Patents, Journal of the American Chemical Society, Journal of Medicinal Chemistry, MedChemComm, Medicinal Research Reviews, Nature Chemical Biology, Scientific Reports, Steroids, Trends in Pharmacological Sciences*

**Memberships**

American Association for Cancer Research

American Association of Colleges of Pharmacy

American Association of Pharmaceutical Scientists

American Chemical Society

American Peptide Society

American Society for Pharmacology and Experimental Therapeutics

Endocrine Society

Rho Chi Pharmacy Honor Society